Xencor to Host Analyst and Investor Event and Webcast on Saturday, November 11, 2017

-- Announced Final Results from Phase 2 Trial of XmAb®5871 in IgG4-Related Disease (IgG4-RD); Plan to Initiate Phase 3 Trial in 2H18 ---- Phase 1b Data from Subcutaneous Administration Trial of XmAb®7195 Show Potent IgE Reduction with Improved Tolerability ---- Management to Host Conference Call Today at 4:30 p.m. ET -

- 12 of 15 (80%) patients completed the study and achieved the primary endpoint of at least a two-point reduction in the IgG4-RD Responder Index on Day 169 -- Eight patients achieved remission (IgG4-RD RI of zero) -- XmAb5871 well tolerated in patients with active IgG4-RD -

MONROVIA, Calif. , Nov. 1, 2017 /PRNewswire/ --   Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

MONROVIA, Calif. , Oct. 31, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release third quarter 2017

-- Accepted for Late-Breaking Abstract Session --

MONROVIA, Calif. , Sept. 20, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

-- Management to Host Conference Call Today at 4:30 p.m. ET --

MONROVIA, Calif. , Aug. 2, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

MONROVIA, Calif. , July 31, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release second quarter